Tulmimetostat Clinical Trials (2026): 5 Studies for Advanced Solid Tumor & Diffuse Large B Cell Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Tulmimetostat clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Advanced Solid Tumor & Diffuse Large B Cell Lymphoma) and 734 total planned enrollment. 4 Tulmimetostat clinical trials are actively recruiting at 29 U.S. sites across 19 states. Most recent activity: NCT07190300 (Aug 2032).
Where to Participate: All Tulmimetostat Trial Sites in the U.S. (29 sites across 19 states)
Every actively recruiting Tulmimetostattrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Univ of Alabama at Birmingham | Birmingham35294-3300 | NCT07190300 | Map |
| CA | VA San Diego Healthcare System, San Diego, CA | San Diego92161-0002 | NCT05467748 | Map |
| CO | Sarah Cannon Research Institute | Denver80218 | NCT07206056 | Map |
| FL | Sarah Cannon Research Institute | Jacksonville32256 | NCT07206056 | Map |
| GA | Emory University | Atlanta30329 | NCT07206056 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30322-1013 | NCT04104776 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT04104776 | Map |
| IA | Uni Of Iowa Hospitals And Clinics | Iowa City52242 | NCT07190300 | Map |
| KS | University of Kansas Cancer Center | Westwood66205 | NCT07190300 | Map |
| KS | Wichita Urology Group PA | Wichita67226 | NCT07190300 | Map |
| KS | Wichita Urology Group PA | Wichita67226 | NCT07206056 | Map |
| MA | Dana Farber Cancer Institute | Boston02215-5450 | NCT04104776 | Map |
| MA | Mass General Hospital | Boston02114 | NCT07206056 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04104776 | Map |
| MI | VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor48105-2303 | NCT05467748 | Map |
| MI | South Texas Accelerated Research Therapeutics (Start) - Midwest Location | Grand Rapids49546 | NCT04104776 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT04104776 | Map |
| NY | NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center | New York10016 | NCT04104776 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT07190300 | Map |
| PA | Abramson Cancer Center of the University of Pennsylvania | Philadelphia19104 | NCT04104776 | Map |
| SC | Medical University of South Carolina MUSC | Charleston29425 | NCT07190300 | Map |
| SC | Carolina Urologic Research Center | Myrtle Beach29572 | NCT07190300 | Map |
| TX | Michael E. DeBakey VA Medical Center, Houston, TX | Houston77030-4211 | NCT05467748 | Map |
| TX | South Texas Accelerated Research Therapeutics | San Antonio78229 | NCT04104776 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT07190300 | Map |
| VA | University of Virginia Health System | Charlottesville22908 | NCT04104776 | Map |
| WA | Fred Hutchinson Cancer | Seattle98109-1023 | NCT04104776 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109-1024 | NCT07206056 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT04104776 | Map |
Tulmimetostat clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 4 | 4 |
Recruiting Tulmimetostat clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07190300 | TulmiSTAR-02TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | P1/P2 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 181 | Jan 2026 |
| NCT07206056 | TulmiSTAR-01An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | P1/P2 | Progressive Metastatic Castrate Resistant Prostate Cancer | 188 | Oct 2025 |
| NCT04104776 | CPI-0209A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | P1/P2 | Advanced Solid Tumor | 275 | Sep 2019 |
| NCT05467748 | EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | P1/P2 | Non Small Cell Lung Cancer | 66 | Dec 2025 |
Tulmimetostat clinical trials by indication
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07190300 | TulmiSTAR-02 | P1/P2 | recruiting | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05467748 | — | P1/P2 | recruiting | EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer |
Progressive Metastatic Castrate Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07206056 | TulmiSTAR-01 | P1/P2 | recruiting | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) |
Mycosis Fungoides (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05944562 | DZR123 | P1 | active not recruiting | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04104776 | CPI-0209 | P1/P2 | recruiting | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas |
All Tulmimetostat trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07190300 | TulmiSTAR-02 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | P1/P2 | recruiting | 181 | Novartis Pharmaceuticals | Jan 2026 |
| NCT07206056 | TulmiSTAR-01 | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | P1/P2 | recruiting | 188 | Novartis Pharmaceuticals | Oct 2025 |
| NCT04104776 | CPI-0209 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | P1/P2 | recruiting | 275 | Novartis Pharmaceuticals | Sep 2019 |
| NCT05467748 | EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | P1/P2 | recruiting | 66 | VA Office of Research and Development | Dec 2025 | |
| NCT05944562 | DZR123 | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | P1 | active not recruiting | 24 | Washington University School of Medicine | Jan 2024 |
Tulmimetostat clinical trials: frequently asked questions
- How many Tulmimetostat clinical trials are there?
- 5 Tulmimetostat clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants.
- Are Tulmimetostat clinical trials recruiting in 2026?
- Yes — 4 Tulmimetostat trials are actively recruiting in 2026, with 29 U.S. sites across 19 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Tulmimetostat being studied for?
- Tulmimetostat is being studied for Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Endometrial Cancer, Lymphoma, T-Cell, Mesothelioma, Malignant and 9 more. The trials are grouped by indication on this page.
- What phase is Tulmimetostat in?
- Tulmimetostat clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Tulmimetostat clinical trials?
- The lead sponsor across the most Tulmimetostat trials is Novartis Pharmaceuticals, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tulmimetostatas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: